Matthew G. Krebs

Matthew G. Krebs


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2012 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JHJian-Mei Hou
Jian-Mei Hou
MKMatthew G. Krebs
Matthew G. Krebs
LLLee Lancashire
Lee Lancashire
RSRobert Szczepaniak Sloane
Robert Szczepaniak Sloane
ABAlison Backen
Alison Backen
CDCaroline Dive
Caroline Dive
Purpose: Circulating tumor cells (CTCs) may have utility as surrogate biomarkers and “virtual” biopsies. We report the clinical significance and molecular characteristics of CTCs and CTC clusters, termed circulating tumor microemboli (CTM), detected in patients with small-cell lung cancer (SCLC) undergoing standard treatment. Patients and Methods: Serial blood samples from 97 patients receiving chemotherapy were analyzed using EpCam-based immunomagnetic detection and a filtration-based technique. Proliferation status (Ki67) and apoptotic morphology were examined. Associations of CTC and CTM number with clinical factors and prognosis were determined. Results: CTCs were present in 85% of patients (77 of 97 patients) and were abundant (mean ± standard deviation = 1,589 ± 5,565). CTM and apoptotic CTCs were correlated with total CTC number and were detected in 32% and 57% of patients, respectively. Pretreatment CTCs, change in CTC number after one cycle of chemotherapy, CTM, and apoptotic CTCs were independent prognostic factors. Overall survival was 5.4 months for patients with ≥ 50 CTCs/7.5 mL of blood and 11.5 months (P < .0001) for patients with less than 50 CTCs/7.5 mL of blood before chemotherapy (hazard ratio = 2.45; 95% CI, 1.39 to 4.30; P = .002). Subpopulations of apoptotic and of proliferating solitary CTCs were detected, whereas neither were observed within cell clusters (CTM), implicating both protection from anoikis and relative resistance to cytotoxic drugs for cells within CTM. Conclusion: Both baseline CTC number and change in CTC number after one cycle of chemotherapy are independent prognostic factors for SCLC. Molecular comparison of CTCs to cells in CTM may provide novel insights into SCLC biology.

20 April 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MKMatthew G. Krebs
Matthew G. Krebs
RSRobert Szczepaniak Sloane
Robert Szczepaniak Sloane
LPLynsey Priest
Lynsey Priest
LLLee Lancashire
Lee Lancashire
JHJian-Mei Hou
Jian-Mei Hou
FBFiona Blackhall
Fiona Blackhall
Purpose: Lung cancer is the leading cause of cancer-related death worldwide. Non–small-cell lung cancer (NSCLC) lacks validated biomarkers to predict treatment response. This study investigated whether circulating tumor cells (CTCs) are detectable in patients with NSCLC and what their ability might be to provide prognostic information and/or early indication of patient response to conventional therapy. Patients and Methods: In this single-center prospective study, blood samples for CTC analysis were obtained from 101 patients with previously untreated, stage III or IV NSCLC both before and after administration of one cycle of standard chemotherapy. CTCs were measured using a semiautomated, epithelial cell adhesion molecule–based immunomagnetic technique. Results: The number of CTCs in 7.5 mL of blood was higher in patients with stage IV NSCLC (n = 60; range, 0 to 146) compared with patients with stage IIIB (n = 27; range, 0 to 3) or IIIA disease (n = 14; no CTCs detected). In univariate analysis, progression-free survival was 6.8 v 2.4 months with P < .001, and overall survival (OS) was 8.1 v 4.3 months with P < .001 for patients with fewer than five CTCs compared with five or more CTCs before chemotherapy, respectively. In multivariate analysis, CTC number was the strongest predictor of OS (hazard ratio [HR], 7.92; 95% CI, 2.85 to 22.01; P < .001), and the point estimate of the HR was increased with incorporation of a second CTC sample that was taken after one cycle of chemotherapy (HR, 15.65; 95% CI, 3.63 to 67.53; P < .001). Conclusion: CTCs are detectable in patients with stage IV NSCLC and are a novel prognostic factor for this disease. Further validation is warranted before routine clinical application.

20 October 2021 in Journal of Clinical Oncology
Verified
Journal Article
Open access
KPKeunchil Park
Keunchil Park
EHEric B. Haura
Eric B. Haura
NLNatasha Leighl
Natasha Leighl
PMPaul Mitchell
Paul Mitchell
CSCatherine A. Shu
Catherine A. Shu
BCByoung Chul Cho
Byoung Chul Cho
PURPOSE: Non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor ( EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors. Amivantamab, an EGFR-MET bispecific antibody with immune cell–directing activity, binds to each receptor's extracellular domain, bypassing resistance at the tyrosine kinase inhibitor binding site. METHODS: CHRYSALIS is a phase I, open-label, dose-escalation, and dose-expansion study, which included a population with EGFR Exon20ins NSCLC. The primary end points were dose-limiting toxicity and overall response rate. We report findings from the postplatinum EGFR Exon20ins NSCLC population treated at the recommended phase II dose of 1,050 mg amivantamab (1,400 mg, ≥ 80 kg) given once weekly for the first 4 weeks and then once every 2 weeks starting at week 5. RESULTS: In the efficacy population (n = 81), the median age was 62 years (range, 42-84 years); 40 patients (49%) were Asian, and the median number of previous lines of therapy was two (range, 1-7). The overall response rate was 40% (95% CI, 29 to 51), including three complete responses, with a median duration of response of 11.1 months (95% CI, 6.9 to not reached). The median progression-free survival was 8.3 months (95% CI, 6.5 to 10.9). In the safety population (n = 114), the most common adverse events were rash in 98 patients (86%), infusion-related reactions in 75 (66%), and paronychia in 51 (45%). The most common grade 3-4 adverse events were hypokalemia in six patients (5%) and rash, pulmonary embolism, diarrhea, and neutropenia in four (4%) each. Treatment-related dose reductions and discontinuations were reported in 13% and 4% of patients, respectively. CONCLUSION: Amivantamab, via its novel mechanism of action, yielded robust and durable responses with tolerable safety in patients with EGFR Exon20ins mutations after progression on platinum-based chemotherapy.

1 June 2014 in Nature Medicine
Verified
Journal Article
Closed access
CHCassandra L Hodgkinson
Cassandra L Hodgkinson
CMChristopher J Morrow
Christopher J Morrow
YLYaoyong Li
Yaoyong Li
RMRobert L Metcalf
Robert L Metcalf
DRDominic Rothwell
Dominic Rothwell
CDCaroline Dive
Caroline Dive

21 January 2014 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
MKMatthew G. Krebs
Matthew G. Krebs
RMRobert L. Metcalf
Robert L. Metcalf
LCLouise Carter
Louise Carter
GBGed Brady
Ged Brady
FBFiona Blackhall
Fiona Blackhall
CDCaroline Dive
Caroline Dive

1 March 2011 in The American Journal of Pathology
Verified
Journal Article
Closed access
JHJian-Mei Hou
Jian-Mei Hou
MKMatthew G. Krebs
Matthew G. Krebs
TWTim Ward
Tim Ward
RSRobert Szczepaniak Sloane
Robert Szczepaniak Sloane
LPLynsey Priest
Lynsey Priest
CDCaroline Dive
Caroline Dive